Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Cholangiocarcinoma 1 Carcinoma, Hepatocellular 1 Bile Duct Neoplasms 1

Interventions

lutetium Lu 177 dotatate 12 Specimen Handling 6 Magnetic Resonance Spectroscopy 6 cabozantinib 5 Everolimus 5 pembrolizumab 4 Nivolumab 4 olaparib 3 lenvatinib 3 Cyclophosphamide 3 177Lu-octreotide, DOTA(0)-Tyr(3)- 3 lanreotide 2 gallium Ga 68 dotatate 2 fludarabine phosphate 2 fludarabine 2 avelumab 2 amino-acid, glucose, and electrolyte solution 2 X-Rays 2 Phantoms, Imaging 2 Octreotide 2 Lutetium-177 2 Ipilimumab 2 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 2 tivozanib 1 surufatinib 1 repotrectinib 1 peposertib 1 pazopanib 1 entrectinib 1 belinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroendocrine Tumors × Yttrium-90 × 90 days × Clear all

NCT04339036 2026-06-04

CapTemY90

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡